Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A ten-week, multicenter, randomized, double-blind, placebo and active-controlled, parallel-group, flexible-dose study evaluating the efficacy, safety, and tolerability of GSK372475 [NS 2359] (1.5 mg/day to 2.0 mg/day) or extended release venlafaxine XR (150 mg/day to 225 mg/day) compared to placebo in adult subjects diagnosed with major depressive disorder

Next Previous
X
Search
Trial Profile

A ten-week, multicenter, randomized, double-blind, placebo and active-controlled, parallel-group, flexible-dose study evaluating the efficacy, safety, and tolerability of GSK372475 [NS 2359] (1.5 mg/day to 2.0 mg/day) or extended release venlafaxine XR (150 mg/day to 225 mg/day) compared to placebo in adult subjects diagnosed with major depressive disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NS 2359 (Primary) ; Venlafaxine
  • Indications Major depressive disorder
  • Focus Proof of concept; Therapeutic Use
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

    • Most Recent Events

    • 21 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
    • 01 May 2012 Results published in the Journal of Psychopharmacology.
    • 10 Dec 2009 Results presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top